NEWS
NUFFIELD HEALTH AND GE HEALTHCARE ANNOUNCE £ 200MILLION COLLABORATION TO INSTALL THE LATEST AI- ENABLED DIAGNOSTIC EQUIPMENT ACROSS UK HOSPITAL NETWORK
Nuffield Health and GE HealthCare have announced a £ 200m collaboration , which will equip Nuffield Health ’ s hospitals with the latest diagnostic imaging technology from GE HealthCare . With access to innovative AI-enabled systems designed to help overcome some of the biggest challenges in healthcare , the collaboration will support Nuffield Health ’ s ambition to deliver an industryleading diagnostic service in the UK . It is also underpinned by a shared commitment to sustainable healthcare , incorporating ongoing upgrades to energy-efficient technology as it evolves .
Through the 20-year Managed Equipment Service ( MES ) agreement , GE HealthCare will take responsibility for the ongoing acquisition , installation , maintenance and staff training for medical technology utilised by Nuffield Health .
The technologies and solutions within the agreement are aimed at providing the best possible care for patients and improving efficiencies for clinicians and other staff for years to come .
In 2025 more than 100 devices are scheduled for delivery across Nuffield Health ’ s national network of hospitals . Nearly 800 pieces of equipment are expected to be delivered over the course of the collaboration across imaging , ultrasound , surgery and x-ray .
Alex Perry , CEO of Nuffield Health , commented : “ GE HealthCare is a leader in medical technology , diagnostics and digital solutions , with more AI-assisted technology than any other supplier .
Healthcare in the UK requires not only investment , but also innovation , making this a transformational partnership . With ongoing technology upgrades over the 20-year span of our agreement , our talented teams will have access to the innovative tools and technology , enabling them to deliver the highest standard of care to patients .”
ROCHE RECEIVES FDA CLEARANCE WITH CLIA WAIVER FOR COBAS LIAT MOLECULAR TESTS TO DIAGNOSE SEXUALLY TRANSMITTED INFECTIONS AT THE POINT OF CARE
Roche has announced that the US Food and Drug Administration ( FDA ) has granted 510 ( k ) clearance and Clinical Laboratory Improvement Amendments of 1988 ( CLIA ) waiver for its cobas liat sexually transmitted infection ( STI ) multiplex assay panels . These panels , including tests for chlamydia and gonorrhea ( CT / NG ) and chlamydia , gonorrhea and Mycoplasma genitalium ( CT / NG / MG ), enable clinicians to diagnose and differentiate between multiple STIs with a single sample . These tests will be exclusively available in the US market in the coming months , with commercialisation under CE mark expected to follow shortly .
“ Rapid molecular point-of-care testing can revolutionise the clinical management of STIs in decentralised and communitybased healthcare settings , enabling informed treatment strategies , better health outcomes for patients , and contain further spread by providing timely diagnosis .” said Matt Sause , CEO of Roche Diagnostics .
More than 1 million people worldwide acquire an STI every day . Common STIs often present overlapping symptoms and can frequently be asymptomatic , making diagnosis challenging , when relying solely on symptoms . Chlamydia trachomatis ( CT ) and Neisseria gonorrhoeae ( NG ) are among the most prevalent STIs . If untreated , these infections can lead to serious health complications , including pelvic inflammatory disease ( PID ), urethritis , ectopic pregnancy , infertility and an increased risk of HIV infection . Additionally , Mycoplasma genitalium ( MG ) is an emerging sexually transmitted pathogen affecting both males and females , with untreated infections resulting in severe health issues such as PID and infertility .
10 www . intelligenthealth . tech